fbpx

Excerpts from the publication

This review included two Cochrane reviews, 14 meta-analyses and 15 trials. Ketamine was studied versus placebo, versus other comparators and as an anesthetic adjuvant before electroconvulsive therapy. In 14 publications, ketamine provided a rapid antidepressant effect with a maximum efficacy reached at 24 hrs. Its effect lasted for 1-2 weeks after infusion, but a longer-term effect is little reported. Ketamine does not seem to improve depressive symptoms at the end of electroconvulsive sessions. Safety and tolerability profiles with ketamine at low single dose are generally good in depressed patients.

Read more

Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review

Zach Walsh, Ozden Merve Mollaahmetoglu, Joseph Rootman, Shannon Golsof, Johanna Keeler, Beth Marsh, David J. Nutt and Celia J. A. Morgan
December 2021

Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa

Sarah-Catherine Rodan, Phillip Aouad, Iain S McGregor, Sarah Maguire
June 2021

Ketamine and depression: a narrative review

Alexandrine Corriger, Gisèle Pickering
August 2019

Chronic, Intermittent Microdoses of the Psychedelic N,N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents

Lindsay P. Cameron, Charlie J. Benson, Brian C. DeFelice, Oliver Fiehn, and David E. Olson
March 2019